Anti-inflammatory *Bifidobacterium* strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice

Shashank Singh¹,², Ruchika Bhatia¹, Pragyanshu Khare¹, Shikha Sharma³, Sivasubramanian Rajammohan⁴, Mahendra Bishnoi⁵, Sanjay Kumar Bhadada⁶, Shyam Sunder Sharma⁷, Jaspreet Kaur²* & Kanthi Kiran Kondepudi¹*

Crohn’s and ulcerative colitis are common inflammatory conditions associated with Inflammatory bowel disease. Owing to the importance of diet based approaches for the prevention of inflammatory gut conditions, the present study was aimed to screen the human isolates of *Bifidobacterium* strains based on their ability to reduce LPS-induced inflammation in murine macrophage (RAW 264.7) cells and to evaluate prioritized strains for their preventive efficacy against ulcerative colitis in mice. Twelve out of 25 isolated strains reduced the production of LPS-induced nitric oxide and inflammatory cytokines. Furthermore, three strains, *B. longum* Bif10, *B. breve* Bif11, and *B. longum* Bif16 conferred protection against dextran sodium sulfate induced colitis in mice. The three strains prevented shortening of colon, spleen weight, percentage body weight change and disease activity index relative to colitis mice. Lower levels of Lipocalin-2, TNF-α, IL-1β and IL-6 and improved SCFA levels were observed in *Bifidobacterium* supplemented mice relative to DSS counterparts. Bacterial composition of *B. longum* Bif10 and *B. breve* Bif11 fed mice was partly similar to the normal mice, while DSS and *B. longum* Bif16 supplemented mice showed deleterious alterations. At the genus level, *Bifidobacterium* supplementation inhibited the abundances of pathobionts such as *Haemophilus*, *Klebsiella* and *Lachnospira* thereby conferring protection.

**Abbreviations**

DSS  Dextran sodium sulfate  
Bif  *Bifidobacterium*  
NO  Nitric oxide  
CFU  Colony forming unit

Crohn’s disease (CD) and Ulcerative colitis (UC) are the inflammatory gut disorders classified under Inflammatory Bowel Disease (IBD). Symptoms of IBD include chronic abdominal pain, bloating, diarrhea, blood in the stool, and inflammation of the gastrointestinal tract (GIT) and symptoms may vary among individuals based on disease location, activity and behavior¹. The rapid rise in the prevalence of IBD across all genders, socioeconomic groups and ethnicities, makes it a burden all over the world including India². India has highest disease burden and rate of incidence of UC in the Asian continent³. Besides physiological and genetic factors, environmental and psychological changes like stress and lifestyle can lead to the onset of IBD⁴. Response to the antibiotic-based treatments of IBD suggests the involvement of intestinal bacteria in the etiology of disease⁵.

¹Healthy Gut Research Group, Food and Nutrition Biotechnology Division, National Agri-Food Biotechnology Institute, S.A.S. Nagar, Punjab 140306, India. ²Department of Biotechnology, University Institute of Engineering and Technology (UIET), Panjab University, Chandigarh 160014, India. ³Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India. ⁴Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar 160062, India. *email: jaspreet_uiet@pu.ac.in; kiran@nabi.res.in
Bacteria and their components like lipopolysaccharide (LPS) leaks through the intestinal wall and translocates into the peripheral organs through disintegrated gut walls. Higher systemic levels of LPS are strongly associated with enhanced inflammation, mucus depletion, increased gut permeability, and that might be responsible for IBD9. Healthy individuals with functional variants in NOD2, IRGM, ATG16L1, CARD9 and FUT2 genes involved in bacterial handling had decreased acetate to butyrate converting Roseburia spp., are at high risk for IBD7. Similarly, muramyl dipeptide (MDP), from Gram positive and negative bacteria, coded through NOD2 is involved in immune responses towards IBD8. Drugs like 5-amino salicylic acid (sulfasalazine and mesalamine), corticosteroids (hydrocortisone or methyl prednisolone) and immuno-modulating drugs Azathioprine and methotrexate are widely used, but have side-effects such as decreased white blood cells, diarrhea, pancreatitis, high blood sugar levels, high blood pressure and insomnia compromising the quality of life9,10. Treatment with monoclonal cytokines, i.e., anti-TNF-α and IL-6, can suppress the inflammatory activity and results in remission of IBD10, but this could not gain popularity owing to its high cost11. Hence, cost effective therapeutic and preventive approaches with minimum side effects are always in demand.

Gut microbial modulation has been suggested as an effective and safer strategy to treat IBD, which can be achieved by including probiotics, prebiotics, symbiotics, cobiotics and phytochemicals such as dietary fibers and polyphenols. Microbial modulation has been shown to be advantageous in multiple immune and inflammation related disorders including obesity12. Among probiotic bacteria, the genera Bifidobacterium is an anaerobic, Gram positive, pleomorphic, and the most vital bacterial genus and is vastly recognized for its health promoting effects on the host. With ageing, the abundance of bifidobacteria declines, while its supplementation has been shown to delay ageing, prevents UC and its associated disorders in animal models13.

Only limited reports exist on Indian isolates of Bifidobacteria with an ability to prevent LPS-induced and DSS induced colonic inflammation. Therefore, the present study was taken up to screen the newly isolated Bifidobacterium strains from infant and adult faeces for their protection against LPS-induced inflammation in murine macrophages. Furthermore, based on the aforesaid property as well as probiotic attributes, B. longum Bif10, B. breve Bif11 and B. longum Bif16 were prioritized and evaluated for their ability to reduce DSS induced colitis in mice.

Results

Screening for Bifidobacterium strains that could reduce nitric oxide production by LPS challenged macrophage cells. Based on the ability of the strains to curtail NO production by LPS induced macrophages and lack of NO production by per se treatment of bacteria on macrophages, Bif6, 10, 11, 12, 14, 16, 17, 20, 29, 30 and 40 were shortlisted for further studies (Table 1). These strains showed reduction in TNF-α, IL-1β and IL-6 production (Table 2). B. longum Bif10, B. breve Bif11, B. longum Bif12 and B. longum Bif16, by virtue of having better reduction ability of inflammatory cytokines and probiotic potentials were short listed for detailed in vitro and in vivo studies.

Effect of various treatments on macrophage cells and determination of NO. There was no reduction in NO production when the macrophages were incubated with killed (autoclaved) Bifidobacterium strains and LPS. Bacterial culture supernatants obtained from the live cultures of B. longum Bif10, B. breve Bif11, B. longum Bif12 and B. longum Bif16 did not inhibit LPS induced NO production by the macrophages.

Study on adhesion of LPS to the bacteria suggested that supernatants obtained from the mixtures of live cells of B. longum Bif10, B. breve Bif11, B. longum Bif12 and B. longum Bif16 and LPS led to 27.6, 25, 25, 35% of NO production by the macrophages while the live cell pellets from the mix caused 21, 26, 4 and 24% of NO production respectively relative to LPS alone treated macrophages (Table 3). Supernatants obtained from the mixtures of dead B. longum Bif10, B. breve Bif11, B. longum Bif12 and B. longum Bif16 and LPS caused 75, 69, 63 and 67% of NO production while the dead cell pellets caused 43, 44, 44 and 48.8% of NO production by the macrophages relative to LPS alone treated macrophages (Table 3).

Based on the above results, B. longum Bif10, B. breve Bif11, B. longum Bif12 and B. longum Bif16 were assessed for their protective role in DSS induced experimental colitis in Balb/c mice.

Bifidobacterium strains protected mice against DSS induced colonic inflammation. DSS treatment slightly decreased the body weight of mice (Fig. 1B); caused 30% mortality (Fig. 1C), decreased the colon length and weight (Fig. 1D,E,F), spleen weight (Fig. 1G) and promoted DAI (Fig. 1H) relative to normal mice. Mice pre-fed with Bifidobacterium strains prior to DSS treatment showed no effect on body weight, no effect on colon length and weight relative to normal mice (Fig. 1B,D,E). Mice in B. breve Bif11 and B. longum Bif16 groups had lower spleen weight, while that in B. longum Bif10 group showed a slight decrease (Fig. 1G) relative to DSS group. Mice in the B. longum Bif10, B. breve Bif11, and B. longum Bif16 showed lower DAI relative to DSS group (Fig. 1H).

Bifidobacterium strains protected mice from DSS induced oxidative stress in colon. DSS treatment decreased the SOD activity and GSH levels; increased the MDA levels, while catalase activity remains unchanged relative to normal mice (Fig. 2A–D). B. longum Bif10 + DSS; B. breve Bif11 + DSS and B. longum Bif16 + DSS fed mice had elevated levels of catalase and GSH, while MDA levels were reduced. SOD remained unchanged relative to DSS alone fed mice.

Bifidobacterium strains protected mice from DSS induced systemic inflammation. DSS treatment enhanced the faecal levels of lipocalin and systemic levels of TNF-α, IL-1β, IL-6 and LPS compared to normal mice, while B. longum Bif10 + DSS; B. breve Bif11 + DSS and B. longum Bif16 + DSS fed mice had lower levels of them relative to
### Table 1. Bifidobacterium strains used in the study and their effect on NO production upon co-treatment with LPS on murine macrophages. Nitric oxide production for untreated RAW cells was 0.85 ± 0.01 μm/ml and for LPS treated RAW cells was 2.3 ± 0.2 μm/ml. Data was analyzed using one-way ANOVA followed by Tukey’s Post-hoc test ($p \leq 0.05$). # Significant relative to LPS treatment. *Significant relative to untreated control; (N = 10).

| Strain          | Source     | NO production (%) | RAW cells + Bif | RAW cells + LPS + Bif |
|-----------------|------------|-------------------|-----------------|-----------------------|
| B. breve Bif 1  | Infant 1   | 58.1 ± 1.5*       | 59.2 ± 3.2*     |
| B. breve Bif 2  | Infant 1   | 45.4 ± 3.3*       | 58.8 ± 3.6*     |
| B. pseudocatenulatum Bif 3 | Infant 2 | 44.2 ± 1.3*       | 4.6 ± 0.6*      |
| B. pseudocatenulatum Bif 4 | Infant 2 | 20.9 ± 1.3*       | 30.7 ± 1.8*     |
| B. longum Bif 6 | Infant 3   | 5.8 ± 0.6         | 7.4 ± 1.2*      |
| B. longum Bif 10 | Infant 4 | 4.0 ± 0.2         | 9.0 ± 1.3*      |
| B. breve Bif 11 | Infant 4   | 11.2 ± 1.4        | 22.2 ± 2.3*     |
| B. longum Bif 12 | Infant 5 | 13.9 ± 1.5        | 19.0 ± 3.4*     |
| B. longum Bif 14 | Infant 5 | 7.2 ± 1.4         | 11.4 ± 2.0*     |
| B. longum Bif 16 | Infant 5 | 6.3 ± 0.4         | 15.4 ± 2.0*     |
| B. longum Bif 17 | Adult 1   | 6.3 ± 0.6         | 8.8 ± 2.2*      |
| B. longum Bif 18 | Adult 1   | 16.3 ± 4.6        | 78.8 ± 3.0*     |
| B. longum Bif 20 | Adult 1   | 4.6 ± 0.3         | 6.7 ± 0.7*      |
| B. bifidum Bif 21 | Adult 1 | 88.3 ± 1.1*       | 87.2 ± 1.1*     |
| B. bifidum Bif 22 | Adult 1   | 45.4 ± 1.3*       | 61.0 ± 2.1*     |
| B. bifidum Bif 23 | Adult 1   | 38.8 ± 3.2*       | 73.2 ± 2.1*     |
| B. bifidum Bif 24 | Adult 1   | 82.5 ± 1.8*       | 90.0 ± 2.7      |
| B. longum Bif 26 | Adult 1   | 22.7 ± 6.0*       | 44.6 ± 1.6*     |
| B. longum Bif 28 | Adult 1   | 7.5 ± 0.5*        | 7.0 ± 0.19*     |
| B. longum Bif 29 | Adult 1   | 22.4 ± 4.3*       | 25.1 ± 5.1*     |
| B. longum Bif 30 | Adult 2   | 5.7 ± 0.5         | 6.4 ± 0.8*      |
| B. pseudocatenulatum Bif 34 | Adult 2 | 21.3 ± 1.4*       | 37.8 ± 3.1*     |
| B. pseudocatenulatum Bif 37 | Adult 2 | 32.0 ± 3.2*       | 43.9 ± 3.7*     |
| B. pseudocatenulatum Bif 38 | Adult 2 | 39.6 ± 2.5*       | 28.9 ± 28.9*     |
| B. breve Bif 40 | VSL#3     | 6.4 ± 1.0         | 11.5 ± 4.2*     |

### Table 2. Effect of Bifidobacteria and LPS co-treatment on pro-inflammatory cytokine production by murine macrophages. Control was untreated RAW cells; LPS control was RAW cells treated with 1 μg/ml LPS. TNF-α, IL-1β and IL-6 for untreated RAW cells were 48.5 ± 14.7 pg/ml; 3.0 ± 0.1 pg/ml and 4.9 ± 3.1 ng/ml respectively while that of LPS treated RAW cells were 4573 ± 58.8 pg/ml; 170 ± 4.5 pg/ml; 1663 ± 10.9 pg/ml respectively. Data was analyzed using one-way ANOVA followed by Tukey’s Post-hoc test ($p \leq 0.05$). #significant relative to LPS treatment; *significant relative to untreated control; (N = 4).

| Strain          | Pro-inflammatory cytokine production |
|-----------------|-------------------------------------|
|                 | TNF-α (pg/ml) | IL-1β (pg/ml) | IL-6 (ng/ml) |
|                 | RAW 264.7 cells + Bif | RAW 264.7 cells + LPS + Bif | RAW 264.7 cells + Bif | RAW 264.7 cells + LPS + Bif |
| B. longum Bif 4 | 2115 ± 78* | 2402 ± 5.9* | 93.3 ± 6.9* | 14.6 ± 0.9* | 48.9 ± 0.1* |
| B. longum Bif 6 | 34.3 ± 9.3 | 47.2 ± 12* | 18.7 ± 3.8* | 3.3 ± 0.3 | 12.1 ± 0.6* |
| B. longum Bif 10 | 50.5 ± 11.3 | 50.5 ± 12* | 21.2 ± 3.6* | 2.7 ± 0.4 | 11.1 ± 1.2* |
| B. breve Bif 11 | 72.12 ± 12.1* | 60.6 ± 19.8* | 29.1 ± 1.7* | 22.5 ± 6.3* | 3.9 ± 1.3 | 42.1 ± 1.8* |
| B. longum Bif 12 | 46.15 ± 5.5 | 98.8 ± 7.3* | 8.4 ± 2.7 | 9.6 ± 3.9* | 3.2 ± 0.2 | 9.7 ± 0.1* |
| B. longum Bif 14 | 28.6 ± 1.3 | 64.8 ± 0.6* | 12.4 ± 4.6 | 33.1 ± 5.2* | 8.1 ± 0.3 | 16.6 ± 1.7* |
| B. longum Bif 16 | 32.1 ± 6.1 | 82.6 ± 9.8* | 4.4 ± 0.7 | 18.8 ± 4.9* | 4.4 ± 0.1 | 6.7 ± 0.4* |
| B. longum Bif 17 | 27.6 ± 6.0 | 121.5 ± 27* | 18.7 ± 4.6 | 24 ± 1.16* | 6.0 ± 0.2 | 18.1 ± 1.2* |
| B. longum Bif 20 | 40.4 ± 0.1 | 141.2 ± 51.6* | 11.6 ± 2.5 | 23.4 ± 1.7* | 9.5 ± 0.1 | 61.2 ± 6.8* |
| B. longum Bif 29 | 209.6 ± 65.4 | 226.8 ± 57.3* | 19.7 ± 4.6 | 26.4 ± 4.5* | 5.6 ± 0.6 | 19.3 ± 2.6* |
| B. longum Bif 30 | 91.2 ± 22.1 | 392.4 ± 1.4* | 22.4 ± 4.8 | 26.4 ± 5.3* | 5.7 ± 1.6 | 24.8 ± 2.4* |
| B. breve Bif 40 | 77.1 ± 26.5 | 100 ± 3.2* | 24.1 ± 0.4 | 19.7 ± 3.3* | 4.0 ± 0.3 | 11.4 ± 1.6* |
DSS alone fed mice (Fig. 2E–I). Importantly, per se supplementation of the strains did not promote their levels relative to normal mice.

*Bifidobacterium* strains modulated DSS induced deleterious gene alterations in the colon. DSS feeding elevated the expression of proinflammatory cytokines such as TNF-α, IL-1β, IL-6 and Ccl5, while it had no effect on MUC-2 expression relative to control mice (Fig. 3A–E). Colon homogenates showed elevated protein levels of TNF-α, IL-1β and IL-6 in the DSS treated mice (Fig. 3F–H). *B. longum* Bif16 + DSS and *B. longum* Bif16 fed mice had levels of these markers similar to normal mice.

*Bifidobacterium* supplementation beneficially modulated the gut microbiota. Illumina paired-end sequencing of the V3-V4 region of the 16S rRNA of the faecal samples suggested that the gut microbiota of the DSS treated mice was different from that of the mice in the control group as determined by PCA (Fig. 4A). *B. longum* Bif10 + DSS and *B. breve* Bif11 + DSS supplemented mice groups clustered together and were partly close to the

### Table 3. Effect of supernatants obtained from live and dead bacteria and LPS mixes on nitric oxide production by the murine macrophages.

| Strains          | % Nitric oxide (NO) production |
|------------------|-------------------------------|
|                  | LPS + live bacteria co-incubation | LPS + dead cells co-incubation |
| RAW cells + Pellet | RAW cells + Supernatant | RAW cells + Pellet | RAW cells + Supernatant |
| *B. longum* Bif 10 | 21.3 ± 0.2₉ | 27.6 ± 0.5₉ | 42.9 ± 0.9₉ | 74.6 ± 1.0₉ |
| *B. breve* Bif 11 | 26.4 ± 0.4⁴ | 25.0 ± 1.8⁴ | 23.9 ± 1.0⁴ | 69.0 ± 1.2⁴ |
| *B. longum* Bif 12 | 19.8 ± 0.4⁴ | 25.1 ± 0.3⁴ | 44.3 ± 1.0⁴ | 62.8 ± 0.2⁴ |
| *B. longum* Bif 16 | 24.0 ± 1.2⁴ | 34.7 ± 3.5⁴ | 48.8 ± 2.4⁴ | 67.2 ± 0.4⁴ |

Data was analyzed using one-way ANOVA followed by Tukey’s Post-hoc test (p ≤ 0.05). *Significant relative to control; #significant relative to control. N = 5.

---

DSS alone fed mice (Fig. 2E–I). Importantly, per se supplementation of the strains did not promote their levels relative to normal mice.

*Bifidobacterium* strains modulated DSS induced deleterious gene alterations in the colon. DSS feeding elevated the expression of proinflammatory cytokines such as TNF-α, IL-1β, IL-6 and Ccl5, while it had no effect on MUC-2 expression relative to control mice (Fig. 3A–E). Colon homogenates showed elevated protein levels of TNF-α, IL-1β and IL-6 in the DSS treated mice (Fig. 3F–H). *B. longum* Bif16 + DSS and *B. longum* Bif16 fed mice had levels of these markers similar to normal mice.

*Bifidobacterium* supplementation beneficially modulated the gut microbiota. Illumina paired-end sequencing of the V3-V4 region of the 16S rRNA of the faecal samples suggested that the gut microbiota of the DSS treated mice was different from that of the mice in the control group as determined by PCA (Fig. 4A). *B. longum* Bif10 + DSS and *B. breve* Bif11 + DSS supplemented mice groups clustered together and were partly close to the
control group indicating that *B. longum* Bif10 and *B. breve* Bif11 supplementation could alleviate the metagenomic changes caused by DSS challenge. However, *B. longum* Bif16 + DSS supplemented mice clustered separately, indicating a very distinct microbial diversity than rest of the groups. Species richness, as determined by the Shannon index and the evenness measure by Gini-Simpson index were almost similar in all the groups (Fig. 4B, C). At the phylum level, a total of 13 phyla were identified in all the samples. The DSS supplementation shifted the microbiome towards higher abundance of Actinobacteria (*p* = 0.004), Firmicutes (*p* = 0.003) and Verrucomicrobia and lower abundance of Bacteroidetes as compared to normal mice (Fig. 4D). *B. breve* Bif11 + DSS and *B. longum* Bif16 + DSS feeding increased the abundance of Actinobacteria in the DSS supplemented mice (*p* = 0.01 and *p* = 0.005 respectively). The relative abundance of Deferribacteres and Proteobacteria in the *B. longum* Bif10 + DSS and *B. breve* Bif11 + DSS supplemented groups was decreased as compared to the DSS fed group and was comparable to the control group (Fig. 4D). The relative abundance of Verrucomicrobia in the *B. breve* Bif11 + DSS supplemented group was decreased as compared to the DSS treated group and comparable to the control group. However, the relative abundances of Verrucomicrobia and Firmicutes were increased in the *B. longum* Bif16 + DSS supplemented group as compared to both the DSS fed and control groups (Fig. 4D).

Specifically, our results suggested that the *B. breve* Bif11 + DSS supplemented group followed by *B. longum* Bif10 + DSS group had the microbiota partly close to the normal mice, which otherwise perturbed by DSS treatment.

At the genus level, DSS treated mice had higher abundances of *Klebsiella*, *Haemophilus* and *Lachnospira* (*p < 0.05) relative to the control mice. *B. longum* Bif10 + DSS, *B. breve* Bif11 + DSS supplemented mice showed lower abundance of *Klebsiella*, *Haemophilus* and *Lachnospira* relative to DSS treated mice while the abundance of these bacteria in the *B. longum* Bif16 + DSS group were similar to that of the DSS group. Per se supplementation of *B. longum* Bif10 and *B. breve* Bif11 did not increase their abundances relative to control, while *B. longum* Bif16 supplementation increased their abundance to the levels of DSS group (Fig. S1).

Co-occurring network between different phyla suggested that in the presence of Actinobacteria, the abundance of Firmicutes, Euryarchaeota and Synergistetes was enhanced, while the abundance of Bacteroidetes,
Cyanobacteria, Tenericutes and Proteobacteria was decreased (Fig. 4E). Similarly, presence of Bacteroidetes results in higher abundance of Cyanobacteria, Tenericutes, TM7 and Proteobacteria, whereas Verrucomicrobia, Firmicutes, Actinobacteria and Synergistetes were decreased. Higher DAI and fecal lipocalin-2 levels were positively correlated with inflammatory markers (TNF-α, IL-1β, IL-6 and LPS) (Fig. 4F). Furthermore, inflammatory markers were inversely related to SCFA (acetate, propionate, lactate and butyrate). Bacteroidetes was positively correlated with lactate, acetate, butyrate while negatively related with propionate. Verrucomicrobia, Actinobacteria and Firmicutes were inversely related with butyrate, acetate and lactate.

**Bifidobacterium strains prevented DSS induced damage to colonic architecture.** Histological analysis of the colon suggested that DSS feeding affected the colonic integrity and architecture along with disruption of crypt structure (Fig. 5A–E). Furthermore, the epithelial layer showed derangements with decreased number of goblet cells and higher number of infiltrated neutrophils upon DSS feeding. Sub-mucosal thickness was increased in DSS fed mice relative to normal mice. Supplementation with *B. longum* Bif10, *B. breve* Bif11 and *B. longum* Bif16 strains before DSS treatment prevented these harmful changes in the colon and conferred protection against colitis.

---

**Figure 4.** Effect of *Bifidobacterium* supplementation on gut microbial changes in DSS induced colitis in mice: (A) PCA analysis; (B) Shannon index; (C) Gini-Simpson index; (D) Bacterial abundance at phylum level; (E) Correlation analysis at phylum level and (F) Correlation analysis among different parameters. Data was analyzed using one-way ANOVA followed by Tukey’s Post-hoc test (*p* ≤ 0.05) for Shannon index, Gini-Simpson index and Bacterial abundance at phylum level. *Significant relative to control; #significant relative to DSS group animals (N = 5).
Bifidobacterium supplementation improved the intestinal barrier function. DSS treated mice had higher levels of FITC-dextran in the serum relative to normal mice, whereas mice supplemented with *B. longum* Bif10, *B. breve* Bif11 and *B. longum* Bif16 along with DSS had lower levels relative to DSS treated mice (Fig. 5F).

*Bifidobacterium* supplementation modulates the SCFA production. DSS treated mice had lower lactate, acetate, propionate and butyrate levels in the caecal content relative to the control mice (Fig. 6). Lactate, acetate, propion-
ate and butyrate were improved in the caecum of mice supplemented with *B. longum* Bif10, *B. breve* Bif11 and *B. longum* Bif16 strains (Fig. 6A–D). Lactate levels were higher in the mice pre-treated with Bif16 (Fig. 6A). Per se treatment with *B. longum* Bif16 showed decreased levels of lactate, acetate and butyrate while that of propionate remained almost the same relative to the normal mice. Per se supplementation with *B. longum* Bif10 and *B. breve* Bif11 did not affect the SCFA levels relative to normal mice, while lactate level was found to be low (Fig. 6A–D).

**Discussion**

Many studies suggested that exogenous administration of *Bifidobacterium* strains improves the health, mainly due to improved barrier function, mucus production and immuno modulation besides the production of anti-microbial peptides, bacteriocins and bioactive exopolysaccharides. Some of the in-vitro and in-vivo studies emphasized the anti-inflammatory potential of *Bifidobacterium* strains. However, reports on anti-inflammatory potential of *Bifidobacterium* strains of Indian origin are scarce. In the present study, based on the ability of bacterial strains (a) to reduce nitric oxide production when treated with LPS on macrophages and (b) no stimulation of nitric oxide production when macrophages treated with *Bifidobacterium* strains alone without LPS treatment, 12 strains were shortlisted out of 25. Medina et al. suggested a lower production or no production of proinflammatory cytokines (TNF-α and MCP-1) by the immune cells when challenged with *B. pseudocatenulatum* CECT 7765 and *B. longum* BB536 and this is a desirable feature to be considered while selecting putative probiotic strains. Similarly, Okada et al. suggested that *Bifidobacterium* species combined with LPS decreased the expression levels of IL12p40, IL-1β and TNF-α by the macrophages in a strain dependent manner and resulted from inhibition of iκB-α phosphorylation and stimulation of SOCS signaling. Our results are in congruence with the aforesaid studies and led to the identification of putative probiotic strains that do not exert pro-inflammatory effect per se on the immune cells.

Furthermore, based on the suppression of TNFα, IL1β and IL-6 production, and probiotic attributes such as high tolerance towards acid and bile, binding to epithelial cells, binding to mucin and utilization of prebiotic isomaltooligosaccharides (unpublished data), four strains namely, *B. longum* Bif10, *B. breve* Bif11, *B. longum* Bif12 and *B. longum* Bif16 were prioritized.

Bacterial adhesion to LPS study indicated that live cells are necessary for efficient binding and elimination of LPS and thereby preventing it from binding to the Toll receptors, thus mitigating the inflammation. We have observed that supernatants from live cells + LPS mix could induce low level of NO by the macrophages, which could be due to the surface proteins on live bifidobacterial cells that could bind and eliminate LPS as suggested by Kondo et al. in *Pediococcus pentosaceous* AK-23 strain where a 217 kDa protein could bind and eliminate 38% of LPS.

As *B. longum* Bif12 and *B. longum* Bif16 were isolated from the same stool sample and likely to be the same strains and since *B. longum* Bif16 showed better reduction in LPS induced IL-6 in addition to TNFa and IL1β, this was preferred over *B. longum* Bif12. Hence, three strains namely, *B. longum* Bif10, *B. breve* Bif11 and *B. longum* Bif16 were further evaluated in the in vivo studies.

Uncontrolled aggravation of intestinal epithelial cells causes mucosal disturbance and ulceration leading to IBD. In this study, clinical conditions of UC were reproducibly induced with 2.5% (W/V) DSS administration in drinking water for seven days, which is due to damage caused to the epithelial monolayer. Supplemetting *B. longum* Bif10, *B. breve* Bif11 and *B. longum* Bif16 strains to the mice protected them from colitis by alleviating crypt distortion, diarrhea, blood in the stool, reduction in colon length, neutrophil infiltration and overall improved survival rate of mice. DAI is also improved in mice fed with these strains. Our results are in alignment with that of earlier researchers where conjugated linoleic acid improved DAI as well as the aforesaid studies and led to the identification of putative probiotic strains that do not exert pro-inflammatory effect per se on the immune cells.

**Harmonious relationship between the gut microbiota and the host is essential for healthy living.** Dysbiosis in microbiota composition leads to aberrant mucosal immunity in the gut as observed in IBD patients. We have observed dysbiosis in the gut bacteria of DSS treated mice, where at the phylum level the abundance of Bacteroidetes and Deferribacters was decreased with DSS treatment, which was similar to the observation by
other researchers\textsuperscript{28}. Actinobacteria levels were low in control than DSS treated mice but increased abundance was found in interventions with \textit{B. longum} Bif10, \textit{B. longum} Bif11 and \textit{B. longum} Bif16 to the mice, suggesting gut modulating effects. Similar results were shown by Cao et al.\textsuperscript{29}. The increase in actinobacteria abundance in the intervention groups might be due to exogenously administered \textit{Bifidobacterium} strains in the respective groups. At the genus level, Klebsiella abundance was increased in DSS treated animals as reported by Zhang et al.\textsuperscript{30}. \textit{Ruminococcus} was found in the gut of IBD patients indicating its role in the onset of colitis\textsuperscript{31}. In our study too, increased abundance of \textit{Ruminococcus} was observed in DSS treated mice. Members of \textit{Blautia}, \textit{Methanobrevibacter}, \textit{Odoribacter} and \textit{Lactobacillus} are the key bacteria involved in SCFA production in large intestine\textsuperscript{32,33}. These bacteria are found in higher abundance in \textit{Bifidobacterium} supplemented mice in this study. PCA, Shannon and Simpson indices suggested the diversity in species and its richness in gut flora between control and DSS as well as in other \textit{Bifidobacterium} treated mice. Co-occurring pattern analysis at the phylum level suggested that \textit{Actinobacteria} abundance was positively correlated with \textit{Firmicutes} and \textit{Synergistetes}. Over all, alterations in gut microbiota in DSS mice might have contributed to colitis, which is counteracted by supplementation with \textit{Bifidobacteria} strains.

The protective role of SCFA against colonic inflammation has been greatly appreciated by many researchers\textsuperscript{33}. SCFAs enhances the gut barrier function and decrease tumor formation in the colon and hence promote colonic health\textsuperscript{34}. In the present study, DSS reduced the levels of lactate, acetate, propionate and butyrate while the three \textit{Bifidobacterial} strains are able to prevent the drop in their levels in the caecum content relative to DSS fed mice. An oral administration of mixture of acetate (67.5 mM), butyrate (40 mM) and propionate (25.9 mM) prevented tumor development and attenuated the colonic inflammation in a mouse model of Aoxymethane (AOM)/Dextran Sodium Sulfate (DSS)-induced colitis-associated colorectal cancer\textsuperscript{35}. Oral acetate administration has been shown to reduce inflammation in high sugar diet induced colitis in mice\textsuperscript{36}. Supplementation with \textit{Bacillus coagulans} MTCC5856 spores and prebiotic whole plant sugar cane fiber decreased the colitis by enhancing intestinal barrier function, reduction in oxidative stress, MPO production and decreased inflammation which in part was mediated through production of propionate and butyrate\textsuperscript{37}. Sodium propionate administration through oral route reduced the symptoms of DSS-induced colitis by promoting intestinal barrier function and suppressing inflammation and oxidative stress through STAT3 pathway\textsuperscript{38}. Butyrate is known to protect the intestinal tissues by promoting mucus production, decreasing inflammation, oxidative stress and exert epigenetic regulation on colonocytes\textsuperscript{38}. The benefits of oral sodium butyrate in drinking water against TNBS induced colitis in mice suggested that butyrate enhanced the intestinal barrier function due to mucin production and reduction in inflammation\textsuperscript{39} and in DSS induced colitis, it increased the expression of \textit{MUC2}, \textit{MUC1}, \textit{MUC3}, and \textit{MUC4}\textsuperscript{40}. However, it is desirable to manipulate the levels of SCFA within the host rather than exogenous administration, which may be challenging for chronic usage and in this context the three strains identified through this study might be useful in modulating the SCFA levels for maintaining healthy intestinal milieu and immunomodulation.

Although, the three strains protected the mice from inflammation, \textit{B. longum} Bif 16 showed slightly lesser effects in relative mRNA levels of TNFa, IL1β and IL-6 as well as having higher abundances of \textit{Haemophilus}, \textit{Klebsiella} and \textit{Lachnospira}.

In conclusion, this study suggested the protective efficacy of \textit{B. longum} Bif10 and \textit{B. breve} Bif11 strains against DSS induced colonic inflammation, which might be due to the direct interaction of the strains with immune cells as demonstrated through in vitro studies as well as through SCFA production that interacts with immune cells and epithelial cells as evidenced in in vivo studies (Fig. 7). SCFAs produced might have contributed to immune modulation, mucin production and probiotic barrier function and by preventing translocation of the pathogen associated molecule, LPS, into the systemic circulation. Furthermore, the protective and therapeutic efficacy of these strains in preclinical models are ongoing.

**Methods**

**Bacterial strains and culture conditions.** Twenty-five \textit{Bifidobacterium} strains isolated from fresh feces of human infants and adults on modified MRS agar containing 0.05% (w/v) each of L-cysteine hydrochloride and mupirocin were used in this study. This study was approved by institute Ethical committee of Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh (ethical approval number: P-641) and all protocols of experimentation and methods were performed in accordance with the relevant guidelines and regulations. Also, informed consent was obtained from both adults and parents of the infants. Active cultures of the strains were prepared from Trypticase soy broth glycerol stocks on MRSC plates and incubated at 37 °C for 48 h under anaerobic conditions. A single colony of each strain from the agar was sub-cultured three times consecutively in fresh MRSC broth at 37 °C for 24 h. Later, the cultures were centrifuged at 8000 rpm for 10 min at 4 °C and the pellets obtained were washed and resuspended in sterile PBS. \textit{B. breve} Bif40, isolated from VSL#3 (De Simone Formulation, manufactured by Sigma-Tau Pharmaceuticals and marketed by Sun pharma) was used as a reference strain in all the in-vitro experiments.

**Screening for \textit{Bifidobacterium} strains that could prevent LPS induced nitric oxide production by murine macrophage cells (RAW 264.7).** RAW 264.7 cell line was purchased from National Centre for Cell Science, Pune, India and cultured in DMEM containing 10% fetal bovine serum and 1% penicillin–streptomycin at 37 °C under 5% CO2 in a humidified incubator. The cells were passaged on every second day.

**Treatment of macrophages with \textit{Bifidobacteria} (Bif) and LPS.** Confluent macrophage cells (1 × 10\textsuperscript{5} cells) were treated with 1 μg/ml LPS and each isolated strain (OD\textsubscript{600} 1 unit = 1 × 10\textsuperscript{10} CFU) for 16 h in a humidified incubator. The supernatants collected were used for the determination of nitric oxide production.
Viability assay. Confluent macrophages in a 96 well cell culture plate was treated with 1.0 OD$_{600}$ of each bacterial strain and incubated at 37 °C under 5% CO$_2$ in a humidified incubator. After 16 h, the supernatants were discarded and the viability of the cells was determined using MTT assay kit (Sigma-Aldrich, USA) as per the instructions.

Effect of various treatments on macrophages and determination of NO. Confluent macrophages were treated with variously processed bacteria as described below, either in the presence or absence of LPS.

Live cells. Live bacterial cells of each strain (1 × 10$^{10}$ CFU ≈ 1.0 OD$_{600}$) were added to the macrophages and incubated for 16 h.

Dead cells. Freshly grown bacterial cultures for 24 h were autoclaved and the cells were harvested by centrifugation, added on the macrophage cells and incubated for 16 h as mentioned above.

Cell free bacterial culture supernatants. Supernatants from the bacterial cultures were obtained from the overnight grown cultures by centrifuging at 8000 rpm for 10 min at 4 °C, filter sterilized using 0.22 μm filters, lyophilized and 0.125, 0.250, 0.5 and 1 mg/ml in DMEM were prepared and added to the macrophages for 16 h as described above.

Adhesion of LPS to live and dead bacteria. This was determined by suspending fresh viable and dead bacterial cells (1.0 OD/ml) in DMEM having 1 μg/ml LPS and incubated at 37 °C under anaerobic conditions for 2 h. The contents were centrifuged and the supernatants and bacterial cells were added to the macrophages and incubated at 37 °C for 16 h under 5% CO$_2$ in a humidified atmosphere.

NO determination. NO was determined using Greiss reagent. Briefly, 100 μl of Griess reagent (2% Sulfanilamide (w/v) in 5% phosphoric acid, 0.2% N-(1-Naphthyl) ethylenediamine dihydrochloride in H$_2$O (w/v)) [1:1]) was added to 150 μl of the supernatants. The level of NO was determined by measuring OD$_{540}$ using ELISA reader.

For the challenging experiments with live and dead bacteria, TNF-α, IL-6 and IL-1β concentrations in the supernatants were determined using commercially available ELISA kits as per the manufacturer’s instructions.

Protection against DSS induced colonic inflammation in mice. Based on in vitro studies on murine macrophages, B. longum Bif10, B. breve Bif11, and B. longum Bif16 were selected for in vivo studies for evaluation of their protective efficacy against DSS induced colitis in Balb/c mice.
Animals. The animal study protocol was approved by Institute Ethical Committee (IAEC/17/57) of National Institute of Pharmaceutical Education and Research, S. A. S. Nagar and all the methods were performed in accordance with the relevant guidelines and regulations as per the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) for experimentation on animals, Govt. of India. Male Balb/c mice aged 8–10-week old were acclimatized for a week under standard experimental conditions at the Central Animal Facility of NIPER, S. A. S. Nagar. Water and food were provided ad libitum.

Experimental groups and treatment schedule. The duration of the experiment was 25 days and the schedule is given in Fig. 1A. Briefly, weight normalized mice were randomized into 8 groups as (1) Control or vehicle group (n = 6), mice were fed with normal pellet diet and gavaged with 200 μl of PBS/vehicle; (2) DSS group (n = 10), mice were ad-libitum provided with 2.5% w/v of DSS in sterile drinking water; (3) *B. longum* Bif10 + DSS group (n = 10), mice were gavaged with *B. longum* Bif10 and DSS; (4) *B. breve* Bif11 + DSS group (n = 10), mice were gavaged with *B. breve* Bif11; (5) *B. longum* Bif16 + DSS group (n = 10), mice were gavaged with *B. longum* Bif16; (6) *B. longum* Bif10 per se group (n = 6), mice were gavaged with *B. longum* Bif10; (7) *B. breve* Bif11 per se group (n = 6), mice were gavaged with *B. longum* Bif11; (8) *B. longum* Bif16 per se group (n = 6), mice were gavaged with *B. longum* Bif16.

Induction of colitis and its prevention using *Bifidobacterium* strains. Colitis in the DSS group was induced by providing DSS (2.5% w/v) in sterile drinking water from the 11th to 18th day. From 19th day onwards, the mice were shifted to normal drinking water till the end of experiment.

Bacterial dose preparation and supplementation. Over-night grown bacterial cultures were centrifuged at 8000 rpm for 10 min at 4 °C and resuspended in PBS after washing. A dose of 2 × 10¹⁰ CFU/ml of bacteria was prepared in trypticase soy broth (TSB) with 15% glycerol and stored at − 80 °C. At the time of dosing, stored bacterial stocks were centrifuged and suspended in approximately 250 μl of PBS and was gavaged to each mouse on every day from the beginning till the end of the experiment while DSS was provided ad-libitum from 11 to 18th day as per the schedule. Body weights of the animals and survival rate were monitored. Change in body weight was determined using the below formula

% body weight change = \[ \left( \frac{\text{weight } D_s - \text{weight } D_0}{\text{weight } D_0} \right) \times 100 \]

where \( D_s \) was body weight at a specific day and \( D_0 \) was body weight at day 0.

Induction of inflammation in various groups was determined by quantifying fecal lipocalin-2 using ELISA kit as per the manufacturer instructions. A Disease activity index (DAI) was calculated using the data on body weight loss (0, < 1%; 1, 1–5%; 2, 5–10%; 3, 10–20%; 4, > 20%), stool consistency (0, normal; 2, loose; 4, diarrhea) and gross bleeding (0, normal color; 2, reddish color; 4, bloody stool) divided by 3 for each mouse.

Evaluation of intestinal permeability. This was evaluated as per Chassaing et al.²⁵. Briefly, on the day of sacrifice (25th day), three mice from each group were starved for 4 h. FITC-dextran (0.6 mg/g body weight; 4–40 KDa, Sigma-Aldrich Co., St. Louis, MO, USA) was gavaged to each animal and after 3 h serum was collected and fluorescence was measured at 488 and 520 nm as excitation and emission wavelengths respectively. Permeability was calculated as the amount of FITC-dextran diffused into the blood circulation from the intestine relative to the normal mice.

Biochemical analysis. Blood was collected from retro-orbital plexus of mice and serum was separated and stored at −80 °C till further analysis. TNF-α, IL-6, IL-1β and LPS levels were measured through commercially available ELISA kits as per the manufacturer’s instructions.

At the end of the experiment, mice were sacrificed by cervical dislocation. Spleen, colon and colonic contents were harvested from each animal. Colon length, weight and spleen weight were determined.

Preparation of proximal colon tissue homogenate. Approximately 50 mg of proximal colon was taken to prepare 10% tissue homogenate in ice cold PBS containing protease inhibitor cocktail using a handheld homogenizer. The homogenate was centrifuged at 12,000 rpm for 15 min at 4 °C and supernatants collected were stored at −20 °C until further use. Protein content in the homogenate was determined by Bradford method. Malondialdehyde level was determined by adding 200 μl of tissue homogenate to 200 μl of 8.1% SDS, 1.5 ml of 20% acetic acid (pH 3.4), 1.5 ml of thiobarbituric acid (0.8%) and 600 μl of H₂O₂ in a test tube and boiled at 95 °C for 1 h in a water bath. The contents were centrifuged at 5000 g for 10 min and the absorbance of the supernatants was measured at 532 nm. The concentration of MDA was expressed as mmol MDA/mg protein of the tissue homogenate. Catalase activity was determined as per Luck.⁴² Briefly, 1.95 ml of phosphate buffer (0.05 M, pH 7.0), 1 ml of hydrogen peroxide (0.019 M) and 0.05 ml of colon tissue homogenate were mixed. Absorbance at 240 nm was measured for 2 min with 30/60 s intervals. Catalase activity was expressed as μMoles of H₂O₂ decomposed per min per mg of protein. Superoxide dismutase was determined as per Kono.⁴³ Briefly, to 0.1 ml of tissue homogenate and 0.5 ml of hydroxylamine hydrochloride (20 mM, pH 6.0 adjusted with NaOH) solution, 2 ml of nitro blue tetrazolium (96 mM, dissolved in 50 mM sodium carbonate in 0.1 mM EDTA, pH 10.8) was added. The auto-oxidation of hydroxylamine was observed by measuring the absorbance at 560 nm for 2 min at 30/60 s intervals. Reduced Glutathione levels were determined as per Ellman method.⁴⁷ Briefly, an equal volumes of tissue homogenate and sulphosalicylic acid were mixed and kept on ice for 1 h, centrifuged at 4500 g for 10 min at
4 °C. To 50 μl of clear supernatant, 450 μl of 0.01 M 5,5-dithiobis-(2-nitrobenzoic acid) in 0.4% of 0.1 M phosphate buffer was added and incubated at 37 °C for 10 min. Absorbance was measured at 412 nm.

**Gene expression analysis in colon tissue.** The list of genes and primer sequences used for RT-PCR are given in Table S1. Total RNA from colon tissue (50 μg) was extracted by Trizol method and quantified on nanodrop (Thermo fisher). cDNA was prepared by reverse transcription kit (Bio Rad, USA; catalogue number 1725035) as per manufacturer instructions. The conditions for RT-PCR were 95 °C for 5 min, 95 °C for 15 s, 60 °C for 30 s, 72 °C for 30 s and 72 °C for 5 min. ΔΔct method was used to determine the relative fold changes in the expression levels of genes using β-actin as the house keeping gene.

**Faecal microbiota analysis.** Genomic DNA was extracted from 100 mg of freshly collected faeces using QIAmp Fast DNA stool mini kit (Qiagen) as per the manufacturer’s instructions and quantified and stored at – 80 °C. The V3–V4 region of the 16S rRNA was sequenced using Illumina HiSeq platform by a commercial company (NxGenBio Life Sciences, New Delhi, India). Reads obtained were quality checked using FastQC (version 0.11.5) on the basis of base quality and sequence quality score distribution. Reads with a threshold value of Q20 or more were used for the analysis. However, majority of the reads had a quality score of Q30 or more (99.9% accuracy). Paired reads were assembled using PEAR (Paired-End reAd mergeR). OTU processing and microbiome analysis were performed by QIIME 1.9.1 and normalization of OTU’s was done by Picrust 1.3.3. Furthermore, Calypso was used to perform taxonomical classification and various analyses (Diversity, PCA, abundance plot, etc.).

**Colon histology.** Colon sections of the mice (n = 3) at the time of sacrifice were stored in 10% phosphate buffered formalin. A small piece of tissue was processed in a series of ethanol and xylene and embedded in molten paraffin. Colonic sections of approximately 5 μm thickness were cut from paraffin embedded tissue blocks using a microtome (Leica, Wetzlar, Germany). Slides were stained with hematoxylin and eosin for microscopic evaluation as per standard methods. On the basis of the architecture of colonic sections, scoring was done for each slide as described elsewhere. Alcian blue staining was done on separate sections to assess the number of mucus producing goblet cells.

**Short chain fatty acid (SCFA) analysis in caecum content.** HPLC method was used for the analysis as described elsewhere. Briefly, 50 mg of the caecal content was extracted with acidified water (pH 1 – 2) by rigorous vortexing followed by incubation at room temperature for 10 min. Contents were centrifuged (6000 rpm, 20 min, 4 °C) and filtered using 0.2 μm nylon filters (Millipore, Millex-GN) and Isobutyric acid (5 μM) was included as an internal standard.

HPLC system (Agilent 1260 infinity series, Agilent Technology, Singapore) equipped with a controller pump (Agilent, model no. G1311C), an auto sampler unit (model no. G1329B) and a diode array detector (DAD; model no. G1315D) set at 210 nm (peak width 2.5 Hz, band width 2 nm) fitted with anion exchange column (Agilent, model no. G1311C), an auto sampler unit (model no. G1329B) and a diode array detector (DAD; an internal standard. The V3–V4 region of the 16S rRNA was sequenced using Illumina HiSeq platform by a commercial company (NxGenBio Life Sciences, New Delhi, India). Reads obtained were quality checked using FastQC (version 0.11.5) on the basis of base quality and sequence quality score distribution. Reads with a threshold value of Q20 or more were used for the analysis. However, majority of the reads had a quality score of Q30 or more (99.9% accuracy). Paired reads were assembled using PEAR (Paired-End reAd mergeR). OTU processing and microbiome analysis were performed by QIIME 1.9.1 and normalization of OTU’s was done by Picrust 1.3.3. Furthermore, Calypso was used to perform taxonomical classification and various analyses (Diversity, PCA, abundance plot, etc.).

Statistical analysis. Graph pad PRISM-5.0 (Graph pad software Inc., CA, USA) software was used for all the analysis. Values were expressed as means ± SEM. Statistical significance between the groups was analyzed One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. p ≤ 0.05 was considered as significant.

Received: 16 June 2020; Accepted: 5 October 2020
Published online: 29 October 2020

**References**

1. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D. C. & Sandborn, W. J. Ulcerative colitis. *Lancet* **380**, 1606 (2012).
2. Kedia, S. & Ahuja, V.. Epidemiology of inflammatory bowel disease in India: The great shift east. *Inflamm. Intest. Dis.* **2**, 102 (2017).
3. Ng, S. C. *et al.* Asia-Pacific Crohn’s and Colitis Epidemiologic Study (ACCESS) Study Group: Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. *Gastroenterology* **145**, 158 (2013).
4. Ananthakrishnan, A. N. Epidemiology and risk factors for IBD. *Nat. Rev. Gastroenterol. Hepatol.* **12**, 205 (2015).
5. Khan, K. J. *et al.* Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. *Am. J. Gastroenterol.* **106**, 661 (2011).
6. Tulkens, J. *et al.* Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction. * Gut* **69**(1), 191–1933 (2020).
7. Imhann, F. *et al.* Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. * Gut* **67**, 108 (2018).
8. Inohara, N. *et al.* Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2. *J. Biol. Chem.* **278**, 5509 (2013).
9. Ardizzoni, S. *et al.* Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. *Gut* **55**, 47 (2006).
10. Neurath, M. F. Cytokines in inflammatory bowel disease. *Nat. Rev. Immunol.* 14, 329 (2014).
11. Sandborn, W. J. & Feagan, B. G. & Marano, C. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. *Gastroenterology* 146, 85 (2014).
12. Porras, D. et al. Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease. *Front. Physiol.* 9, 1813 (2018).
13. Zhang, Y. et al. Probiotic mixture protects dextran sulfate sodium induced colitis by altering tight junction protein expressions and increasing Tregs. *Mediators Inflamm.* 2018, 9416391 (2018).
14. Fedorak, R. N. Probiotics in the management of ulcerative colitis. *Gastroenterol. Hepatol.* 6, 688 (2010).
15. Linares, D. M. et al. Lactic acid bacteria and *Bifidobacteria* with potential to design natural biofunctional health-promoting dairy foods. *Front. Microbiol.* 8, 846 (2017).
16. Imaoka, A. et al. Anti-inflammatory activity of probiotic *Bifidobacterium*: Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. *World J. Gastroenterol.* 14, 2511 (2008).
17. Medina, M., Izquierdo, E., Ennahar, S. & Sanz, Y. Differential immunomodulatory properties of *Bifidobacterium* logum strains: Relevance to probiotic selection and clinical applications. *Clin. Exp. Immunol.* 150(3), 531–538 (2007).
18. Okada, Y. et al. Anti-inflammatory effects of the genus *Bifidobacterium* on macrophages by modification of *phospho-I kappaB* and SOCS gene expression. *Int. J. Exp. Pathol.* 90(2), 131–140 (2009).
19. Kondo, A. et al. Isolation of endotoxin eliminating lactic acid bacteria and a property of endotoxin eliminating protein. *J. Food Sci.* 81(6), M1457–M1465 (2016).
20. Chassaing, B., Aitken, J. D., Malleshappa, M. & Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr. Protoc. Immunol.* 04, 25.1.1 (2014).
21. Tan, S. et al. A ropy exopolsaccharide producing strain *Bifidobacterium* longum subsp longum Y108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation. *Food Funct.* 10, 1595 (2019).
22. Sanz, Y. & De Palma, G. Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function *Int. Rev. Immunol.* 28, 397 (2009).
23. Jin, B., Sun, T., Yu, X. H., Yang, Y. X. & Yeo, A. E. T. The effects of TLR activation on T-cell development and differentiation. *Clin. Dev. Immunol.* 2012, 836485 (2012).
24. Mantovani, A. et al. The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol.* 25, 677 (2004).
25. Chassaing, B. et al. Fecal lipocalin-2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. *PLoS ONE* 7, e44328 (2012).
26. Nishida, A. et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin. J. Gastroenterol.* 11, 1–10 (2018).
27. Kang, C. S. et al. Extracellular vesicles derived from gut microbiota, especially *Akckermania muciniphila*, protect the progression of dextran sulfate sodium-induced colitis. *PLoS ONE* 8, e76520 (2013).
28. Cao, G. et al. *Bacillus amyloquefaciens* ameliorates dextran sulfate sodium induced colitis by improving gut microbial dysbiosis in mice model. *Front. Microbiol.* 9, 3260 (2019).
29. Zhang, Q. et al. Accelerated dysbiosis of gut microbiota during aggravation of DSS-induced colitis by a butyrate-producing bacterium. *Sci. Rep.* 6, 27572 (2016).
30. Allebe, Z. et al. The anti-inflammatory IFITM genes ameliorate colitis and partially protect from tumorigenesis by changing immunity and microbiota. *Immunol. Cell. Biol.* 96, 284 (2018).
31. Lee, B., Yin, X., Griffey, S. M. & Marco, M. L. Attenuation of colitis by *Lactobacillus casei* BL23 is dependent on the dairy delivery matrix. *Appl. Environ. Microbiol.* 81, 6425 (2015).
32. Parada, V. D. et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. *Front. Immunol.* 10, 277 (2019).
33. Hijova, E. & Chmelarova, A. Short chain fatty acids and colonic health. *Bratisl. Lek Listy* 108(8), 354–358 (2007).
34. Fedorak, R. et al. Oral acetate reduces a high sugar diet induced increased susceptibility to colitis. *Gastroenterol. Clin.* 38, 277 (2019).
35. Tian, Y., Xu, Q., Sun, L., Ye, Y. & Ji, G. Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. *J. Nutr. Biochem.* 57, 103 (2018).
36. Tong, L. C. et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress. *Pharmacol. 7, 253 (2016).*
37. Shinde, T. et al. Synthetic supplementation containing whole plant sugar cane fibre and probiotic spores potentiates protective synergistic effects in mouse model of IBD. *Nutrients* 11, 819 (2019).
38. Chen, G. et al. Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. *EBioMedicine* 30, 317 (2018).
39. Chen, J., Zhao, K. N. & Vitetta, L. Effects of intestinal microbial elaborated butyrate on oncogenic signaling pathways. *Nutrients* 11, 1026 (2019).
40. Hoebler, C., Gaudier, E., De Coppeet, P., Rival, M. & Cherbut, C. MUC genes are differently expressed during onset and maintenance of inflammation in dextran sodium sulfate-treated mice. *Dig. Dis.* 51, 381 (2006).
41. Touni, M. et al. Probiotic bacteria *lactobacillus* and *Bifidobacterium* attenuate inflammation in dextrate sodium sulfate-induced experimental colitis in mice. *Int. J. Immunopathol. Pharmacol.* 27, 615 (2014).
42. Luck, H. Catalase: In *Methods of Enzymatic Analysis* (Ed. H. U. Bergmeyer), 885–888 (Academic Press, New York, 1963).
43. Kono, T. Generation of superoxide radical during autoxidation of hydroxyamine and an assay for superoxide dismutase *Arch. Biochem. Biophys.* 186, 189 (1978).
44. Ellman, G. L. Tissue sulfydryl group. *Arch Biochem Biophys.* 82, 70 (1959).
45. Singh, D. P. et al. A novel cobiotic based preventive approach against high fat diet-induced adiposity, non-alcoholic fatty liver and gut derangement in mice. *Int. J. Obes.* 40, 487 (2016).

Acknowledgements

All the authors would like to thank NABI and Department of Biotechnology (DBT), Government of India for the financial support. Shashank Singh gratefully acknowledge NABI for providing fellowship throughout the research work. Authors would like to thank DBT-eLibrary Consortium (DeCON) for providing online literature resources. Thanks to Dr. Sasikumar Elumalai, Scientist-D, Centre of Innovative and Applied Bioprocessing, Mohali, India for the help in making graphical abstract.

Author contributions

K KK, MB & SKB conceptualized and designed the study; Shashank Singh, KKK, MB, SKB, SSS and JK wrote and edited the manuscript; Shashank Singh, SKB and KKK performed the isolations and characterization of bacterial strains; Shashank Singh and RB performed RT-PCR assays; Shashank Singh, PK, Shikha Sharma, SSS
and KKK performed the animal studies. Shashank Singh, Sivasubramanian Rajarammohan and KKK performed the metagenomic data analysis.

**Competing interests**
The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at [https://doi.org/10.1038/s41598-020-75702-5](https://doi.org/10.1038/s41598-020-75702-5).

Correspondence and requests for materials should be addressed to J.K. or K.K.K.

Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Creative Commons Attribution 4.0 International License](http://creativecommons.org/licenses/by/4.0/)

© The Author(s) 2020